c21

Selective protein arginine methyltransferase 1 (PRMT1) inhibitor (IC50 = 1.8 μM). Exhibits five-fold selectivity for PRMT1 over PRMT6 and >250-fold selectivity over PRMT3 and CARM1.

Qingyangshengenin (Cynanchagenin) 是一种孕烷糖苷，是一种分离自Cychuchumot ophyllum(Asclepiadaceae) 的根中的 C21 类固醇糖苷配基。它具有抗癌作用。

DOCK5-IN-C21 is an allosteric inhibitor of the guanine nucleotide exchange factor DOCK5.

Buloxibutid (AT2 receptor agonist C21) 是一种新型且具有选择性小分子 angiotensin II AT2 receptor (血管紧张素 II AT2 受体)激动剂，对 AT2 受体和 AT1 受体的 Ki 值分别为 0.4 nM 和 10 μM。

Heneicosanoic acid (C21:0) 是广泛存在于动植物中的长链饱和脂肪酸。

11(Z),14(Z),17(Z)-Eicosatrienoic acid methyl ester is the ester derivative of 11(Z),14(Z),17(Z)-eicosatrienoic acid, identified within lipid-producing microalgae Nannochloropsis, as well as in diesel-contaminated soils and residential wastewater.

12(Z),15(Z)-Heneicosadienoic acid, an ω-6 very long-chain polyunsaturated fatty acid, serves as a positional isomer of heneicosadienoic acid, which is scarcely found in living organisms.

CC214-1 是一种 mTOR 抑制剂，具有潜在的抗癌活性，抑制蛋白翻译，可诱导自噬 (autophagy)。 CC214-1 是探索 mTOR 激酶生物学的体外工具化合物，可用于研究骨髓瘤。

ONC212 是氟化 ONC201 类似物，是有前景的抗癌剂。它也是 GPR132的选择性激动剂，可诱导凋亡。

DRI-C21045 是一种有效的 CD40-CD40L 协同刺激蛋白-蛋白质相互作用的选择性抑制剂，IC50 为 0.17 μM。它显示对 CD40L 诱导的 NF-κB 活化和 B 细胞增殖的浓度依赖性抑制，IC50分别为 17.1 μM 和 4.5 μM。

TRC210258 is a TGR5 agonist that acts by decreasing glycemic and dyslipidemic cardiovascular risk in animal models of diabesity.

MC2184 是人重组 SIRT1 的抑制剂。

CC214-2 is a potent dual inhibitor of mTORC1 and mTORC2, known for its ability to impede autophagy by modulating mammalian target of rapamycin (mTOR) signaling. With this capacity, CC214-2 shows promise in shortening the duration of tuberculosis (TB) [1].

BSc2118 is a potent proteasome inhibitor. BSc2118 shows significant antimyeloma activity and may be considered as a promising agent in cancer drug development. BSc2118 is also a promising new candidate for stroke therapy, which may in addition alleviate recombinant tissue-plasminogen activator-induced brain toxicity.

NVP-CFC218 is a novel potent and selective p53-HDM2 inhibitor.

DRI-C21041 (DIEA)是一种IC50值为0.31 μM的CD40 CD40L相互作用抑制剂，能够抑制同种异体抗原诱导的免疫反应。

DRI-C21041，作为一种针对CD40 CD40L相互作用的抑制剂，其IC50为0.31 μM，能够抑制由同种异体抗原诱导的免疫反应。

ATAC21是一种连接子免疫刺激化合物，它通过含琥珀酰亚胺基团的稳定型马来酰亚胺-PEG4连接子与免疫刺激化合物结合而成。ATAC21能够与SBT-040（抗CD40抗体）结合，形成具有免疫激活作用的偶联物。

BNC210 (IW-2143) 是一种α7 nAChR 负变构调节剂，在焦虑和抑郁动物模型中有活性。

53BP1-binding protein 1 (53BP1) engages with dimethylated lysine 20 on histone 4 (H4K20me2) through its tandem tudor domains within a homodimer configuration, crucial for the DNA damage response. UNC2170, a micromolar 53BP1 ligand, selectively interacts with this site, demonstrating at least 17-fold preference for 53BP1 over similar proteins. This interaction occurs in a pocket formed by the 53BP1's tudor domains. Moreover, UNC2170 acts as an antagonist to 53BP1 in cellular lysates, effectively inhibiting class switch recombination, a process dependent on the functional 53BP1 tudor domain, thus confirming its cellular activity.

XC219 (compound 43) 作为一种CDK(细胞周期蛋白依赖性激酶)抑制剂,能够与CDK的Lys活性位点发生共价结合.此化合物主要应用于抗真菌研究领域.

BC21, 作为一种β-catenin Tcf4抑制剂，主要通过阻断β-catenin与Tcf4衍生肽的结合，从而有效地抑制β-catenin Tcf4引导的报告基因活性。该化合物广泛应用于癌症相关的研究领域。

ONC213 作为一种αKGDH抑制剂，主要通过降低αKGDH活性来抑制线粒体呼吸，并提升α-酮戊二酸的含量，进而促使AML细胞发生凋亡（Apoptosis）。该化合物主要用于急性髓性白血病的研究领域。

3-Hydroxyanisole对MAO-A具有抑制活性(IC50=24±2.8 μM），可用于研究神经和精神疾病。